1
|
Burg CM, Backhaus P, Tio J, Neri D, Cazzamalli S, Heindel W, Schäfers M. Erste Erfahrungen mit dem neuen Liganden 68Ga-OncoFAP zur Darstellung des Fibroblasten-Aktivierungs-Protein (FAP) im Brustkrebs-Staging mittels PET-MRT. ROFO-FORTSCHR RONTG 2022. [DOI: 10.1055/s-0042-1749847] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- C M Burg
- Universitätsklinikum Münster, Klinik für Radiologie, Münster
| | - P Backhaus
- Universitätsklinikum Münster, Klinik für Nuklearmedizin, Münster
| | - J Tio
- Universitätsklinikum Münster, Klinik für Frauenheilkunde und Geburtshilfe, Bereich Senologie, Münster
| | - D Neri
- Department Chemie und angewandte Biowissenschaften, ETH Zürich und Philogen SpA, Zürich, Schweiz und Siena, Italien
| | | | - W Heindel
- Universitätsklinikum Münster, Klinik für Radiologie, Münster
| | - M Schäfers
- Universitätsklinikum Münster, Klinik für Nuklearmedizin, Münster
| |
Collapse
|
2
|
Müther M, Roll W, Zinnhardt B, Schäfers M, Rahbar K, Brokinkel B, Stummer W. P09.05 177Lu-DOTATATE therapy in progressive meningioma. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND
Progressive meningioma is a challenging condition with a decreasing number of treatment options over the course of disease. Neurovascular involvement and multifocal disease often complicate surgical management. In addition, repeated radiotherapy carriers a risk of side effects. In somatostatin receptor expressing meningioma, peptide receptor radiotherapy (PPRT) with 177Lu-DOTATATE poses a promising alternative. However, current evidence is scarce. Hereby we present our single center experience of (PPRT) with 177Lu-DOTATATE in progressive meningioma.
METHODS
Eight patients (median age: 71 years; range 56–77) with progressive meningioma underwent PRRT using 177Lu-DOTATATE were included in this retrospective analysis. Response to therapy was assessed by interim and post-therapy 68Ga-DOTATATE-PET-CT and MRI. 177Lu-DOTATATE scintigraphies 48h p.i. were evaluated according to Krenning scale. Additionally, clinical outcome and follow up imaging were analyzed for progression free interval times.
RESULTS
Eight patients were included: Six patients with grade II and two patients with grade I meningiomas, according to the 2016 WHO classification. Six of eight patients harbored multifocal disease. One patients suffered systemic metastatic disease. Patients received a median of three cycles (range: 1 - 5) of PRRT with 177Lu-DOTATATE (mean injected dose 7.1 GBq) between 1/2015 and 1/2019. Tumor uptake in 48h p.i. 177Lu-Scintigraphies was heterogeneous (Krenning scale; median: 3; range: 1–4). Post-therapy imaging scheduled eight weeks after completion of therapy showed progressive disease in five patients, three patients had stable disease. Median follow-up post therapy response evaluation was 24 months in patients with stable disease. Median time to progression was 10 months.
CONCLUSION
In this cohort of eight progressive meningioma patients 177Lu-DOTATATE therapy showed heterogeneous efficacy.
Collapse
Affiliation(s)
- M Müther
- University Hospital Münster, Dept. of Neurosurgery, Münster, Germany
| | - W Roll
- University Hospital Münster, Dept. of Nuclear Medicine, Münster, Germany
| | - B Zinnhardt
- University Hospital Münster, Dept. of Nuclear Medicine, Münster, Germany
| | - M Schäfers
- University Hospital Münster, Dept. of Nuclear Medicine, Münster, Germany
| | - K Rahbar
- University Hospital Münster, Dept. of Nuclear Medicine, Münster, Germany
| | - B Brokinkel
- University Hospital Münster, Dept. of Neurosurgery, Münster, Germany
| | - W Stummer
- University Hospital Münster, Dept. of Neurosurgery, Münster, Germany
| |
Collapse
|
3
|
Müther M, Roll W, Stegger L, Zinnhardt B, Schäfers M, Weckesser M, Rahbar K, Stummer W. P14.67 Somatostatin receptor targeted radioligand therapyin head and neck paraganglioma. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz126.302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
BACKGROUND
Surgical resection is the therapy of choice in head and neck paraganglioma. However, surgery is associated with significant morbidity depending on tumor size and localization. In case of progressive residual or recurrent disease, new and less aggressive therapeutic options are warranted. Somatostatin receptor (SSTR) targeted therapies pose a promising alternative, as SSTRs are upregulated in paragangliomas. Only few studies provide evidence on efficacy of 177Lu-DOTATATE therapy in these patients. The aim of this study was to evaluate the efficacy of peptide receptor radiotherapy (PPRT) with 177Lu-DOTATATE for head and neck paragangliomas.
METHODS
A total of seven consecutive patients (mean age: 60 years, range: 14–84) with progressive head and neck paragangliomas (3 carotid body tumors, 4 jugulotympanic paragangliomas), treated with PRRT using 177Lu-DOTATATE, were included in this retrospective analysis. Therapy response was assessed by interim and post-therapy 68Ga-DOTATATE-PET-CT and MRI according to morphological and SSTR imaging parameters. Therapeutic uptake was classified on177Lu-DOTATATE scintigraphies 48h p.i. according to the Krenning scale. Longer-term clinical and imaging-based outcome were evaluated.
RESULTS
Patients received a median of 4 cycles (range: 3 to 5) of PRRT with 177Lu-DOTATATE (mean injected dose 7.3 GBq). Interim and post-therapy staging showed at least stable disease in all patients. Tumor uptake in 48h p.i. 177Lu-scintigraphies was moderate to high in all patients (Krenning scale; median: 3; range: 2–4). Furthermore, none of the patients showed progressive disease during the median follow-up time of 28 months (range: 6–37 months).
CONCLUSION
SSTR targeted therapy using 177Lu-DOTATATE shows promising efficacy and may lead to long lasting stable disease.
Collapse
Affiliation(s)
- M Müther
- University Hospital Münster, Dept. of Neurosurgery, Münster, Germany
| | - W Roll
- University Hospital Münster, Dept. of Nuclear Medicine, Münster, Germany
| | - L Stegger
- University Hospital Münster, Dept. of Nuclear Medicine, Münster, Germany
| | - B Zinnhardt
- University Hospital Münster, Dept. of Nuclear Medicine, Münster, Germany
| | - M Schäfers
- University Hospital Münster, Dept. of Nuclear Medicine, Münster, Germany
| | - M Weckesser
- University Hospital Münster, Dept. of Nuclear Medicine, Münster, Germany
| | - K Rahbar
- University Hospital Münster, Dept. of Nuclear Medicine, Münster, Germany
| | - W Stummer
- University Hospital Münster, Dept. of Neurosurgery, Münster, Germany
| |
Collapse
|
4
|
Kurch L, Hasenclever D, Kluge R, Georgi T, Tchavdarova L, Golombeck M, Sabri O, Eggert A, Brenner W, Sykora KW, Bengel FM, Rossig C, Körholz D, Schäfers M, Feuchtinger T, Bartenstein P, Ammann RA, Krause T, Urban C, Aigner R, Gattenlöhner S, Klapper W, Mauz-Körholz C. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial. Pediatr Blood Cancer 2019; 66:e27539. [PMID: 30426671 DOI: 10.1002/pbc.27539] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2018] [Revised: 10/11/2018] [Accepted: 10/14/2018] [Indexed: 11/06/2022]
Abstract
PURPOSE In 2014, we published the qPET method to quantify fluorodeoxyglucose positron emission tomography (FDG-PET) responses. Analysis of the distribution of the quantified signals suggested that a clearly abnormal FDG-PET response corresponds to a visual Deauville score (vDS) of 5 and high qPET values ≥ 2. Evaluation in long-term outcome data is still pending. Therefore, we analyzed progression-free survival (PFS) by early FDG-PET response in a subset of the GPOH-HD2002 trial for pediatric Hodgkin lymphoma (PHL). PATIENTS/METHODS Pairwise FDG-PET scans for initial staging and early response assessment after two cycles of chemotherapy were available in 93 PHL patients. vDS and qPET measurement were performed and related to PFS. RESULTS Patients with a qPET value ≥ 2.0 or vDS of 5 had 5-year PFS rates of 44%, respectively 50%. Those with qPET values < 2.0 or vDS 1 to 4 had 5-year PFS rates of 90%, respectively 80%. The positive predictive value of FDG-PET response assessment increased from 18% (9%; 33%) using a qPET threshold of 0.95 (vDS ≤ 3) to 30% (13%; 54%) for a qPET threshold of 1.3 (vDS ≤ 4) and to 56% (23%; 85%) when the qPET threshold was ≥ 2.0 (vDS 5). The negative predictive values remained stable at ≥92% (CI: 82%; 98%). CONCLUSION Only strongly enhanced residual FDG uptake in early response PET (vDS 5 or qPET ≥ 2, respectively) seems to be markedly prognostic in PHL when treatment according to the GPOH-HD-2002 protocol is given.
Collapse
Affiliation(s)
- L Kurch
- Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany
| | - D Hasenclever
- Institute of Medical Statistics, Informatics and Epidemiology, University of Leipzig, Leipzig, Germany
| | - R Kluge
- Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany
| | - T Georgi
- Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany
| | - L Tchavdarova
- Clinic of Nuclear Medicine, National Hospital for Active Treatment in Oncology, Sofia, Bulgaria
| | - M Golombeck
- Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany
| | - O Sabri
- Department of Nuclear Medicine, University Hospital of Leipzig, Leipzig, Germany
| | - A Eggert
- Division of Pediatric Hematology and Oncology, Department of Pediatrics, Charité Berlin, Berlin, Germany
| | - W Brenner
- Department of Nuclear Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - K W Sykora
- Department of Pediatric Hematology and Oncology, Medizinische Hochschule Hannover, Hannover, Germany
| | - F M Bengel
- Department of Nuclear Medicine, Medizinische Hochschule Hannover, Hannover, Germany
| | - C Rossig
- University Children's Hospital Münster, Pediatric Hematology and Oncology, Münster, Germany
| | - D Körholz
- Division of Pediatric Hematology and Oncology, Department of Pediatrics, Justus-Liebig University of Giessen, Giessen, Germany
| | - M Schäfers
- Department of Nuclear Medicine, University Hospital of Münster, Münster, Germany
| | - T Feuchtinger
- Dr. von Hauner University Children's Hospital, LMU Munich, Munich, Germany
| | - P Bartenstein
- Department of Nuclear Medicine, LMU Munich, Munich, Germany
| | - R A Ammann
- Division of Pediatric Hematology and Oncology, Department of Pediatrics (Inselspital) Bern University Hospital, University of Bern, Bern, Switzerland
| | - T Krause
- Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
| | - C Urban
- Division of Pediatric Hematology and Oncology, Department of Pediatrics, University Hospital Graz, Graz, Austria
| | - R Aigner
- Department of Radiology, Medical University Graz, Graz, Austria
| | - S Gattenlöhner
- Department of Pathology, Justus-Liebig University of Giessen, Giessen, Germany
| | - W Klapper
- Department of Pathology, University Hospital of Kiel, Kiel, Germany
| | - C Mauz-Körholz
- Division of Pediatric Hematology and Oncology, Department of Pediatrics, Justus-Liebig University of Giessen, Giessen, Germany.,Medical Faculty, Martin-Luther-University of Halle-Wittenberg, Halle, Germany
| |
Collapse
|
5
|
Oertel M, Scobioala S, Kroeger K, Baehr A, Stegger L, Haverkamp U, Schäfers M, Eich HT. Worth a local treatment? - Analysis of modern radiotherapy concepts for oligometastatic prostate cancer. Radiat Oncol 2018; 13:185. [PMID: 30241556 PMCID: PMC6150968 DOI: 10.1186/s13014-018-1118-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Accepted: 08/29/2018] [Indexed: 12/03/2022] Open
Abstract
Background Prostate cancer (PCA) is the most-prevalent non-skin cancer in men worldwide. Nevertheless, the treatment of oligometastatic, especially lymph-node (ln) recurrent, PCA remains elusive. The aim of our study was to provide insights in radiotherapy (RT)-treatment of recurrent PCA exhibiting ln- or osseous (oss)-oligometastases. Methods Between April 2012 and April 2017, 27 oligometastatic PCA patients (19 ln and 8 single oss) were treated with RT at our institution. Results The metastasis-free survival (MFS) was 24.8 m (22.0–36.0 m) and 25.4 m (23.9–28.1 m) for the ln- and oss-subgroup resulting in 1-year MFS of 75.4 and 100% and 2-year MFS of 58.7 and 83.3% for ln- and oss-metastatic patients, respectively. Of notice, none of the recurrences for ln-patients was in the RT-field, constituting a local control of 100%. Within the ln-group, pre-RT median-PSA was 2.6 ng/ml, median post-RT PSA was 0.3 ng/ml, which was significant (p = 0.003). Median biochemical-free survival (bfS) was 12.2 m. PCA that was initially confined to the prostate had a better bfS (p < 0.001) and MFS (p = 0.013). The oss-group had a median PSA of 4.9 ng/ml pre-treatment which dropped to a median value of 0.14 ng/ml (p = 0.004). Toxicities were moderate, with only 1 case of III° toxicity. There were no deaths in the ln-group, thus overall survial was 100% here. Conclusion Our study points out the feasibility of RT as a treatment option in recurrent PCA and demonstrates an excellent local control with a low-toxicity profile.
Collapse
Affiliation(s)
- M Oertel
- Department of Radiation Oncology, Albert-Schweitzer Campus 1 A1, 48149, Muenster, Germany.
| | - S Scobioala
- Department of Radiation Oncology, Albert-Schweitzer Campus 1 A1, 48149, Muenster, Germany
| | - K Kroeger
- Department of Radiation Oncology, Albert-Schweitzer Campus 1 A1, 48149, Muenster, Germany
| | - A Baehr
- Department of Radiation Oncology, Albert-Schweitzer Campus 1 A1, 48149, Muenster, Germany
| | - L Stegger
- Department of Nuclear Medicine, Albert-Schweitzer Campus 1 A1, 48149, Muenster, Germany
| | - U Haverkamp
- Department of Radiation Oncology, Albert-Schweitzer Campus 1 A1, 48149, Muenster, Germany
| | - M Schäfers
- Department of Nuclear Medicine, Albert-Schweitzer Campus 1 A1, 48149, Muenster, Germany
| | - H-T Eich
- Department of Radiation Oncology, Albert-Schweitzer Campus 1 A1, 48149, Muenster, Germany
| |
Collapse
|
6
|
Ahmadzadehfar H, Albers P, Bockisch A, Boegemann M, Böhme C, Burchert W, Dietlein M, Drzezga A, Fabry U, Feldmann G, Heidenreich A, Heinzel A, Herrmann K, Heyll A, Höhling C, Kreuzer C, Laufer D, Mengel R, Mottaghy FM, Müller HW, Müller SC, Ost E, Rahbar K, Reifenhäuser W, Schäfers M, Schlenkhoff C, Schmidt M, Schmidt-Wolf I, Wildenhain C, Zimmer B, Essler M. [Lutetium-177-PSMA radioligand therapy : Consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein]. Urologe A 2018; 57:709-713. [PMID: 29671080 DOI: 10.1007/s00120-018-0642-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
In the last 3 years, Lutetium-177 prostate-specific membrane antigen radioligand therapy (Lu-177-PSMA-RLT) has received increasing attention in nuclear medicine as a new form of treatment for castration-resistant metastatic prostate cancer. This therapy combines the radionuclide Lutetium-177, which has been therapeutically used in nuclear medicine for many years, with a molecular target of the transmembrane prostate-specific membrane antigen expressed by prostate cancer cells. Since there are no prospective randomized studies on Lu-177-PSMA-RLT and the question of reimbursement has repeatedly been the subject of review by the MDK Nordrhein (Medischenische Dienst der Krankenversicherung), there was a desire because of the increasing number of patients being treated to clarify under which circumstances Lu-177-PSMA-RLT can be reimbursed by German statutory health insurance. The goals of this article are to help treating physicians understand how this new therapy option works, to integrate it in the overall therapy concept for castration-resistant metastatic prostate cancer, and, above all, to use Lu-177-PSMA-RLT-based on the current data-at the right place in the therapy sequence of castration-resistant metastatic prostate cancer.
Collapse
Affiliation(s)
- H Ahmadzadehfar
- Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Deutschland.
| | - P Albers
- Klinik für Urologie, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
| | - A Bockisch
- Klinik für Nuklearmedizin, Universitätsklinikum Essen, Essen, Deutschland
| | - M Boegemann
- Klinik für Urologie und Kinderurologie, Universitätsklinikum Münster, Münster, Deutschland
| | - C Böhme
- Abteilung für Medizin-Controlling, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
| | - W Burchert
- Herz- und Diabeteszentrum Bad Oeynhausen, Klinik für Nuklearmedizin, Bad Oeynhausen, Deutschland
| | - M Dietlein
- Klinik für Nuklearmedizin, Universitätsklinikum Köln, Köln, Deutschland
| | - A Drzezga
- Klinik für Nuklearmedizin, Universitätsklinikum Köln, Köln, Deutschland
| | - U Fabry
- Abteilung für Medizin-Controlling, Universitätsklinikum Aachen, Aachen, Deutschland
| | - G Feldmann
- Medizinische Klinik und Poliklinik III, Universitätsklinikum Bonn, Bonn, Deutschland
| | - A Heidenreich
- Klinik für Urologie, Universitätsklinikum Köln, Köln, Deutschland
| | - A Heinzel
- Klinik für Nuklearmedizin, Uniklinikum Aachen, Aachen, Deutschland
| | - K Herrmann
- Klinik für Nuklearmedizin, Universitätsklinikum Essen, Essen, Deutschland
| | - A Heyll
- KC Onkologie des GKV-SV und der MDK-Gemeinschaft, Düsseldorf, Deutschland
| | - C Höhling
- AOK Rheinland/Hamburg, Düsseldorf, Deutschland
| | - C Kreuzer
- MFB Stationäre Versorgung, MDK Nordrhein, Düsseldorf, Deutschland
| | - D Laufer
- Abteilung für Medizin-Controlling, Universitätsklinikum Bonn, Bonn, Deutschland
| | - R Mengel
- MFB Stationäre Versorgung, MDK Nordrhein, Düsseldorf, Deutschland
| | - F M Mottaghy
- Klinik für Nuklearmedizin, Uniklinikum Aachen, Aachen, Deutschland
| | - H-W Müller
- Klinik für Nuklearmedizin, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
| | - S C Müller
- Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Bonn, Bonn, Deutschland
| | - E Ost
- KC Onkologie des GKV-SV und der MDK-Gemeinschaft, Düsseldorf, Deutschland
| | - K Rahbar
- Klinik für Nuklearmedizin, Universitätsklinikum Münster, Münster, Deutschland
| | - W Reifenhäuser
- Abteilung für Medizin-Controlling, Universitätsklinikum Köln, Köln, Deutschland
| | - M Schäfers
- Klinik für Nuklearmedizin, Universitätsklinikum Münster, Münster, Deutschland
| | - C Schlenkhoff
- Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Deutschland
| | - M Schmidt
- Klinik für Nuklearmedizin, Universitätsklinikum Köln, Köln, Deutschland
| | - I Schmidt-Wolf
- Abteilung für Integrierte Onkologie - CIO Bonn, Universitätsklinikum Bonn, Bonn, Deutschland
| | - C Wildenhain
- Abteilung für Medizin-Controlling, Universitätsklinikum Düsseldorf, Düsseldorf, Deutschland
| | - B Zimmer
- KC Onkologie des GKV-SV und der MDK-Gemeinschaft, Düsseldorf, Deutschland
| | - M Essler
- Klinik und Poliklinik für Nuklearmedizin, Universitätsklinikum Bonn, Sigmund-Freud-Str. 25, 53127, Bonn, Deutschland
| |
Collapse
|
7
|
Kurth J, Krause BJ, Schwarzenböck SM, Stegger L, Schäfers M, Rahbar K. External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies. EJNMMI Res 2018; 8:32. [PMID: 29651569 PMCID: PMC5897276 DOI: 10.1186/s13550-018-0386-4] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Accepted: 04/02/2018] [Indexed: 12/26/2022] Open
Abstract
Background Prostate-specific membrane antigen (PSMA)-targeted therapy with 177Lu-PSMA-617 is a therapeutic option for patients with metastatic castration-resistant prostate cancer (mCRPC). To optimize the therapy procedure, it is necessary to determine relevant parameters to define radiation protection and safety necessities. Therefore, this study aimed at estimating the ambient radiation exposure received by the patient. Moreover, the excreted activity was quantified. Results In total, 50 patients with mCRPC and treated with 177Lu-PSMA-617 (mean administered activity 6.3 ± 0.5 GBq) were retrospectively included in a bi-centric study. Whole-body dose rates were measured at a distance of 2 m at various time points after application of 177Lu-PSMA-617, and effective half-lives for different time points were calculated and compared. Radiation exposure to the public was approximated using the dose integral. For the estimation of the excreted activity, whole body measurements of 25 patients were performed at 7 time points. Unbound 177Lu-PSMA-617 was rapidly cleared from the body. After 4 h, approximately 50% and, after 12 h, approximately 70% of the administered activity were excreted, primarily via urine. The mean dose rates were the following: 3.6 ± 0.7 μSv/h at 2 h p. i., 1.6 ± 0.6 μSv/h at 24 h, 1.1 ± 0.5 μSv/h at 48 h, and 0.7 ± 0.4 μSv/h at 72 h. The mean effective half-life of the cohort was 40.5 ± 9.6 h (min 21.7 h; max 85.7 h). The maximum dose to individual members of the public per treatment cycle was ~ 250 ± 55 μSv when the patient was discharged from the clinic after 48 h and ~ 190 ± 36 μSv when the patient was discharged after 72 h. Conclusions In terms of the radiation exposure to the public, 177Lu-PSMA is a safe option of radionuclide therapy. As usually four (sometimes more) cycles of the therapy are performed, it must be conducted in a way that ensures that applicable legal requirements can be followed. In other words, the radiation exposure to the public and the concentration of activity in wastewater must be sub-marginal. Therefore, in certain countries, hospitalization of these patients is mandatory.
Collapse
Affiliation(s)
- J Kurth
- Department of Nuclear Medicine, Rostock University Medical Center, Gertrudenplatz 1, 18057, Rostock, Germany.
| | - B J Krause
- Department of Nuclear Medicine, Rostock University Medical Center, Gertrudenplatz 1, 18057, Rostock, Germany
| | - S M Schwarzenböck
- Department of Nuclear Medicine, Rostock University Medical Center, Gertrudenplatz 1, 18057, Rostock, Germany
| | - L Stegger
- Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany
| | - M Schäfers
- Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany
| | - K Rahbar
- Department of Nuclear Medicine, University Hospital Muenster, Muenster, Germany
| |
Collapse
|
8
|
Häsfeld M, Schober O, Matheja P, Schäfers M, Budde T, Hammel D, Scheid H, Breithardt G, Bartenstein P. 201TI Reinjection Predicts Improvement of Left Ventricular Function following Revascularization. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1629649] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryThe aim of this study was to evaluate the correlation between improved TI uptake in reinjection imaging with improvements in regional wall motion and global ejection fraction following PTCA or aorto-coronary bypass surgery. 19 patients with CHD were investigated and divided into two groups according to their thallium uptake in the reinjection studies. Group I showed additional uptake on reinjection imaging compared to the redistribution image, whereas group II showed no additonal uptake. Both groups had a similar number and distribution of affected vessels and location of the leading stenosis. Stress, redistribution and reinjection images were obtained prior to revascularization and evaluated semiquantitatively from a bulls eye scheme. There was a postoperative increase in regional wall motion in group I from 5.3 to 8.8% whereas group II did not show a relevant change (6.3 vs 6.0%). The ejection fraction increased from 55.0 to 66.7% in group I and dit not increase in group II (59.8 vs 58.7%). The overall predictive value of the reinjection image for improvement in wall motion (> 10%) was 91 % and for the redistribution image 58%. Increased uptake in reinjection imaging predicts improved ventricular function following revascularization and indeed indicates viable myocardium with reversible functional impairment.
Collapse
|
9
|
Schäfers M, Gietzen F, Schäfers K, Kuwert T, Kuhn H, Schober O, Lerch H. Myocardial Perfusion and Metabolism After Transcoronary Ablation of Septum Hypertrophy (TASH) in Hypertrophic Obstructive Cardiomyopathy. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1629743] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryOutflow obstruction constitutes a major problem in hypertrophic obstructive cardiomyopathy (HOCM) and may be treated by transcoronary injection of ethanol into septal arteries (transcoronary ablation of septum hypertrophy, TASH). We report on myocardial perfusion and glucose metabolism in a 50 year old man in whom TASH led to a reduction of septal thickness (9 vs. 26 mm), a sustained elimination of the outflow tract obstruction (resting gradient 0 vs. 60 mmHg; postES-gradient 10 vs. 145 mmHg) and a substantial clinical improvement (NYHA stage II vs. Il-lll) without impairment of global ventricular function (left ventricular ejection fraction 0.62 vs. 0.64). After TASH, perfusion and glucose metabolism were assessed by positron emission tomography (PET) using F-18-fluorodeoxyglucose (F-18-FDG) and Tc-99m-MIBI single photon emission tomography (SPECT). TASH results in matched reduction of perfusion and glucose consumption in a circumscribed area fed by the septal branch used for ethanol injection. No remote effects were observed. TASH leads to a sharply delineated septal reduction of perfusion and metabolism with consecutive reduction of septal thickness, a sustained elimination of the outflow tract obstruction, and a substantial clinical improvement without impairment of global ventricular function.
Collapse
|
10
|
Diehl B, Kuwert T, Stodieck SRG, Schäfers M, Schäfers K, Schuierer G, Ringelstein E, Schober O, Matheja P. Measurement of Temporal Asymmetries of Glucose Consumption Using Linear Profiles: Reproducibility and Comparison with Visual Analysis. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1629791] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary
Aim: One approach to regionally analyze temporal glucose consumption consists in drawing linear profiles over the maximal values measured in the temporal cortical ribbon. The aim of our study was to test the reproducibility of this method and to compare its diagnostic performance to that of visual analysis in patients with complex partial seizures (CPS). Methods: Regional cerebral glucose consumption (rCMRGIc) was measured interictally in 25 CPS patients and 10 controls using F-18-deoxyglucose and the positron emission tomography (PET) camera ECAT EXACT 47. The PET scans were visually analyzed for the occurrence of unilateral temporal hypermetabolism. Furthermore, rCMRGIc was quantified on six contiguous coronal planes by manually tracing maximal values of temporal glucose consumption, thus creating line profiles of temporal glucose consumption for each side. Indices of asymmetry (ASY) were then calculated from these line profiles in four temporal regions and compared to the corresponding 95% confidence intervals of the control data. All analyses were performed by two observers independently from each other and without knowledge of the clinical findings. Results: The agreement between the two observers with regard to focus lateralization was 96% (κ = 0.93) on visual analysis and 100% (κ = 1) on quantitative analysis. There was an excellent agreement with regard to focus lateralization between visual and quantitative evaluation (κ = 0.8). Conclusion: Quantitation of local temporal rCMRGIc by using linear profile analysis is highly reproducible; for the lateralization of epileptogenic foci, however, this method does not possess significant advantages over the visual evaluation of the scans.
Collapse
|
11
|
Bengel F, Büll U, Burchert W, Kies P, Kluge R, Krause BJ, Lindner O, Nienaber C, Nowak B, Schäfer W, Schober O, Schwaiger M, Silber S, Stegger L, vom Dahl J, Zimmermann R, Schäfers M. Position paper nuclear cardiology: Update 2008. Nuklearmedizin 2018. [DOI: 10.3413/nukmed-0220] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
SummaryNuclear cardiology is well established in clinical diagnostic algorithms for many years. This is an update 2008 of the first common position paper of the German Association of Nuclear Medicine and the German Association of Cardiology, Heart and Circulation Research published in 2001 aiming at an overview of state-of-the-art scintigraphic methods.
Collapse
|
12
|
Abstract
Summary:Motion in PET/CT leads to artifacts in the reconstructed PET images due to the different acquisition times of positron emission tomography and computed tomography. The effect of motion on cardiac PET/CT images is evaluated in this study and a novel approach for motion correction based on optical flow methods is outlined. The Lukas-Kanade optical flow algorithm is used to calculate the motion vector field on both simulated phantom data as well as measured human PET data. The motion of the myocardium is corrected by non-linear registration techniques and results are compared to uncorrected images.
Collapse
|
13
|
Abstract
SummaryNuclear cardiological procedures have paved the way for non-invasive diagnostics of various partial functions of the heart. Many of these functions cannot be visualised for diagnosis by any other method (e. g. innervation). These techniques supplement morphological diagnosis with regard to treatment planning and monitoring. Furthermore, they possess considerable prognostic relevance, an increasingly important issue in clinical medicine today, not least in view of the cost-benefit ratio.Our current understanding shows that effective, targeted nuclear cardiology diagnosis – in particular for high-risk patients – can contribute toward cost savings while improving the quality of diagnostic and therapeutic measures.In the future, nuclear cardiology will have to withstand mounting competition from other imaging techniques (magnetic resonance imaging, electron beam tomography, multislice computed tomography). The continuing development of these methods increasingly enables measurement of functional aspects of the heart. Nuclear radiology methods will probably develop in the direction of molecular imaging.
Collapse
|
14
|
Law MP, Kopka K, Wagner S, Luthra S, Pike VW, Neumann J, Kirchhefer U, Schmitz W, Schober O, Schäfers M, Riemann B. High non-specific binding of the β1-selective radioligand 2-125I-ICI-H. Nuklearmedizin 2018. [DOI: 10.1055/s-0038-1625187] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Summary:
Aim: As results of cardiac biopsies suggest, myocardial β1-adrenoceptor density is reduced in patients with chronic heart failure. However, changes in cardiac β2-adrenoceptors vary. With suitable radiopharmaceuticals single photon emission computed tomography (SPECT) and positron emission tomography (PET) offer the opportunity to assess β-adrenoceptors non-invasively. Among the novel racemic analogues of the established β1-selective adrenoceptor antagonist ICI 89.406 the iodinated 2-I-ICI-H showed high affinity and selectivity to β1-adrenoceptors in murine ventricular membranes. The aim of this study was its evaluation as a putative sub-type selective β1-adrenergic radioligand in cardiac imaging. Methods: Competition studies in vitro and in vivo were used to investigate the kinetics of 2-I-ICI-H binding to cardiac β-adrenoceptors in mice and rats. In addition, the radiosynthesis of 2-125I-ICI-H from the silylated precursor 2-SiMe3-ICI-H was established. The specific activity was 80 GBq/µmol, the radiochemical yield ranged from 70 to 80%.
Results: The unlabelled compound 2-I-ICI-H showed high β1-selectivity and -affinity in the in vitro competition studies. In vivo biodistribution studies apparently showed low affinity to cardiac β-adrenoceptors. The radiolabelled counterpart 2-125I-ICI-H showed a high degree of non-specific binding in vitro and no specific binding to cardiac β1-adrenoceptors in vivo. Conclusion: Because of its high non-specific binding 2-125I-ICI-H is no suitable radiotracer for imaging in vivo.
Collapse
|
15
|
Abstract
SummaryAlpha- and beta-adrenoceptors play an important role in the control of heart function. According to their molecular, biological, and pharmacological characteristics, they are subdivided into α1-, α2- and β1-, β2-, β3-, β4-adrenoceptors. In cardiac disease, there is often a selective downregulation of β1-adrenoceptors associated with a relative increase in β2- and α1-adrenoceptors. Functional imaging techniques like single-photon emission tomography (SPECT) and positron emission tomography (PET) provide the unique capability for non-invasive assessment of cardiac adrenoceptors. Radioligands with high specific binding to cardiac α- and β-adrenoceptors suitable for radiolabelling are required for clinical studies. The non-selective β-adrenoceptor antagonist [11C]CGP-12177 was used to quantify β-adrenoceptor density using PET in patients with heart disease. New non-selective ligands (e. g. [11C]CGP-12388, [18F]CGP-12388, [11C]carazolol and [18F]fluorocarazolol) are currently evaluated; β1-selective radioligands (e. g. [11C]CGP-26505, [11C]bisoprolol, [11C]HX-CH 44) and β2-selective radioligands (e. g. [11C]formoterol, [11C]ICI-118551) were assessed in animals. None of them turned out as suitable for cardiac PET.Potential radioligands for imaging cardiac α1-adrenoceptors are based on prazosin. Whereas [11C]prazosin shows low specific binding to myocardium, its derivative [11C]GB67 looks more promising. The putative α2-adrenoceptor radioligand [11C]MK-912 shows high uptake in rodent myocardium but has not yet been evaluated in man.A number of radioligands were evaluated for assessing cardiac adrenoceptors using PET. New radioligands are needed to provide more insight into cardiac pathophysiology which may influence the therapeutic management of patients with cardiovascular disease.
Collapse
|
16
|
Burchert W, Bengel FM, Zimmermann R, vom Dahl J, Schäfer W, Büll U, Schober O, Schwaiger M, Kluge R, Schäfers M, Lindner O. Myocardial perfusion scintigraphy in Germany. Nuklearmedizin 2018. [DOI: 10.1055/s-0037-1621023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryThe working group Cardiovascular Nuclear Medicine of the German Society of Nuclear Medicine (DGN), in cooperation with the working group Nuclear Cardiology of the German Cardiac Society (DGK), decided to conduct a national survey on myocardial perfusion scintigraphy (MPS). Method: A questionnaire to evaluate MPS for the year 2005 was sent. Results: 346 completed questionnaires had been returned (213 private practices, 99 hospitals and 33 university hospitals). MPS of 112 707 patients were reported with 110 747 stress and 95 878 rest studies. The majority (>75%) was performed with 99mTc-MIBI or tetrofosmin. 201Tl stress-redistribution was used in 22 637 patients (20%). The types of stress were exercise in 78%, vasodilation with adenosine or dipyridamol in 21% and dobutamine in 1%. 99.97% of all MPS were SPECT studies. Gated SPECT was performed in 36% of the stress and in 32% of the rest studies. An attenuation correction was used in 21%. 29 institutions (8%) performed gated SPECT (stress and rest) and attenuation correction. 47% of all MPS were requested by ambulatory care cardiologists, 17% by internists, 12% by primary care physicians, 21% by hospital departments and 2% by others. Conclusion: In Germany, MPS is predominantly performed with 99mTc-perfusion agents. The common type of stress is ergometry. Gated SPECT and attenuation correction do not yet represent standards of MPS practice in Germany, which indicates some potential of optimization.
Collapse
|
17
|
Abstract
SummaryOptical imaging has long been considered a method for histological or microscopic investigations. Over the last 15 years, however, this method was applied for preclinical molecular imaging and, just recently, was also able to show its principal potential for clinical applications (e.g. fluorescence-guided surgery). Reviewing the development and preclinical evaluation of new fluorescent dyes and target-specific dye conjugates, these often show characteristic patterns of their routes of excretion and biodistribution, which could also be interesting for the development and optimization of radiopharmaceuticals. Especially ionic charges show a great influence on biodistribution and netcharge and charge-distribution on a conjugate often determines unspecific binding or background signals in liver, kidney or intestine, and other organs.Learning from fluorescent probe behaviour in vivo and translating this knowledge to radio-pharmaceuticals might be useful to further optimize emerging and existing radiopharmaceuticals with respect to their biodistribution and thereby availability for binding to their targets.
Collapse
|
18
|
Burchert W, Bengel FM, Zimmermann R, vom Dahl J, Schäfer W, Schober O, Kluge R, Schäfers M, Lindner O. Myocardial perfusion scintigraphy 2006 in Germany. Nuklearmedizin 2018. [DOI: 10.3413/nukmed-0158] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
SummaryAim: This second survey was to deliver further information on myocardial perfusion scintigraphy (MPS) in Germany in 2006. Method: 351 questionnaires were evaluated: 207 private practices (PP), 117 hospitals (HO), 27 from university hospitals (UH). Results: MPS of 106 331 patients were reported, 85% were investigated with 99mTc-perfusion tracers. 74% [2005=72%] were performed in PP, 17% [2005=15%] in HO and 9% [2005=13%] in UH. PP, which participated in 2005 and 2006, demonstrated an increase by 3,9% (HO 0%, UH –13,0%). The type of stress was pharmacological in 27% [2005=22%]; 54% adenosine (of these 29% with exercise), 37% dipyridamole (of these 56% with exercise), and 9% dobutamine. Gated SPECT was performed in 42% [2005=36%] of all restand in 39% [2005=32%] of all stress MPS. An attenuation correction was used by 69 [2005=78] institutions. 40% of all MPS were performed in patients suspected to have CAD. 24% of all institutions reported changes in the use of MPS by competing methods. Conclusion: There is a small increase of MPS between 2005 and 2006 despite competing methods. Gated SPECT has experienced more acceptance. Suspicion of CAD is an important indication of MPS. In order to tap the full potential of MPS a gated SPECT should be performed routinely.
Collapse
|
19
|
Galstyan A, Block D, Niemenn S, Riehemann K, Strassert C, Faust A, Schäfers M, Dobrindt U. Conjugated phthalocyanines as light driven antibiotics. Photodiagnosis Photodyn Ther 2017. [DOI: 10.1016/j.pdpdt.2017.01.124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
20
|
Bailey DL, Pichler BJ, Gückel B, Barthel H, Beer AJ, Botnar R, Gillies R, Goh V, Gotthardt M, Hicks RJ, Lanzenberger R, la Fougere C, Lentschig M, Nekolla SG, Niederdraenk T, Nikolaou K, Nuyts J, Olego D, Riklund KÅ, Signore A, Schäfers M, Sossi V, Suminski M, Veit-Haibach P, Umutlu L, Wissmeyer M, Beyer T. Combined PET/MRI: from Status Quo to Status Go. Summary Report of the Fifth International Workshop on PET/MR Imaging; February 15-19, 2016; Tübingen, Germany. Mol Imaging Biol 2016; 18:637-50. [PMID: 27534971 PMCID: PMC5010606 DOI: 10.1007/s11307-016-0993-2] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
This article provides a collaborative perspective of the discussions and conclusions from the fifth international workshop of combined positron emission tomorgraphy (PET)/magnetic resonance imaging (MRI) that was held in Tübingen, Germany, from February 15 to 19, 2016. Specifically, we summarise the second part of the workshop made up of invited presentations from active researchers in the field of PET/MRI and associated fields augmented by round table discussions and dialogue boards with specific topics. This year, this included practical advice as to possible approaches to moving PET/MRI into clinical routine, the use of PET/MRI in brain receptor imaging, in assessing cardiovascular diseases, cancer, infection, and inflammatory diseases. To address perceived challenges still remaining to innovatively integrate PET and MRI system technologies, a dedicated round table session brought together key representatives from industry and academia who were engaged with either the conceptualisation or early adoption of hybrid PET/MRI systems. Discussions during the workshop highlighted that emerging unique applications of PET/MRI such as the ability to provide multi-parametric quantitative and visual information which will enable not only overall disease detection but also disease characterisation would eventually be regarded as compelling arguments for the adoption of PET/MR. However, as indicated by previous workshops, evidence in favour of this observation is only growing slowly, mainly due to the ongoing inability to pool data cohorts from independent trials as well as different systems and sites. The participants emphasised that moving from status quo to status go entails the need to adopt standardised imaging procedures and the readiness to act together prospectively across multiple PET/MRI sites and vendors.
Collapse
Affiliation(s)
- D L Bailey
- Department of Nuclear Medicine, Royal North Shore Hospital, and Faculty of Health Sciences, University of Sydney, Sydney, Australia
| | - B J Pichler
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard-Karls-Universität, Tübingen, Germany
| | - B Gückel
- Department of Interventional and Diagnostic Radiology, Eberhard-Karls-Universität, Tübingen, Germany
| | - H Barthel
- Department of Nuclear Medicine, University Clinic, Leipzig, Germany
| | - A J Beer
- Department of Nuclear Medicine, Ulm University, Ulm, Germany
| | - R Botnar
- Division of Imaging Sciences and Biomedical Engineering, King's College London, London, UK
| | | | - V Goh
- Division of Imaging Sciences and Biomedical Engineering, Department of Cancer Imaging, King's College London, London, UK
| | - M Gotthardt
- Department of Nuclear Medicine, Radboud University, Nijmegen, The Netherlands
| | - R J Hicks
- Peter MacCallum Cancer Centre, Melbourne, Australia
| | - R Lanzenberger
- Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
| | - C la Fougere
- Division of Nuclear Medicine and clinical Molecular Imaging, Department of Radiology, University of Tübingen, Tübingen, Germany
| | - M Lentschig
- ZEMODI, Zentrum für Moderne Diagnostik, Bremen, Germany
| | - S G Nekolla
- Department of Nuclear Medicine, Technical University Munich, Munich, Germany
| | - T Niederdraenk
- Strategy and Innovation Technology Center, Siemens Healthcare GmbH, Erlangen, Germany
| | - K Nikolaou
- Department of Interventional and Diagnostic Radiology, Eberhard-Karls-Universität, Tübingen, Germany
| | - J Nuyts
- Department of Imaging and Pathology, Nuclear Medicine and Molecular Imaging, KU Leuven - University of Leuven, Leuven, Belgium
| | - D Olego
- Philips, 3000 Minuteman Road, Andover, MA, 01810, USA
| | - K Åhlström Riklund
- Department of Diagnostic Radiology, Radiation Sciences, Umeå University/Norrlands University Hospital, Umeå, Sweden
| | - A Signore
- Nuclear Medicine Unit, Departments of Medical-Surgical Sciences and Translational Medicine, "Sapienza" University of Rome, Rome, Italy
| | - M Schäfers
- Department of Nuclear Medicine, University Hospital Münster and European Institute for Molecular Imaging, University of Münster, Münster, Germany
| | - V Sossi
- Department of Physics and Astronomy, University of British Columbia, Vancouver, Canada
| | | | - P Veit-Haibach
- Department of Nuclear Medicine, University Hospital Zurich, Zurich, Switzerland
| | - L Umutlu
- Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany
| | - M Wissmeyer
- Department of Nuclear Medicine, University Hospital of Geneva, Geneva, Switzerland
| | - T Beyer
- Center for Medical Physics and Biomedical Engineering, General Hospital Vienna, Medical University Vienna, 4L, Waehringer Guertel 18-20, 1090, Vienna, Austria.
| |
Collapse
|
21
|
Hansen T, Weckesser M, Schäfers M, Gunnemann A. [Uncommon manifestation of prostate cancer : Sister Mary Joseph's nodule]. Urologe A 2016; 56:50-53. [PMID: 27272004 DOI: 10.1007/s00120-016-0130-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
We report on the case of an 81-year-old man suffering from prostate cancer for several years. In recent months, PSA levels increased, and 68Ga-PSMA-PET-CT (PSMA: prostate-specific membrane antigen) imaging demonstrated suspicious lesions in the paravesical area and an umbilical tumor mass. Local excision was performed. Histologically, the tumor mass was diagnosed as metastasis of the prostate cancer, which is also designated as Sister Mary Joseph's nodule. Umbilical metastases of primary prostate cancer are extremely rare; however, they are of clinical importance since they are commonly associated with tumor progress and with a particularly poor prognosis.
Collapse
Affiliation(s)
- T Hansen
- Institut für Pathologie, Klinikum Lippe GmbH, Röntgenstraße 18, 32756, Detmold, Deutschland.
| | - M Weckesser
- Klinik für Nuklearmedizin, Universitätsklinikum Münster, Münster, Deutschland
| | - M Schäfers
- Klinik für Nuklearmedizin, Universitätsklinikum Münster, Münster, Deutschland
| | - A Gunnemann
- Klinik für Urologie, Klinikum Lippe GmbH, 32756, Detmold, Deutschland
| |
Collapse
|
22
|
Faust A, Hermann S, Schäfers M, Höltke C. Optical imaging probes and their potential contribution to radiotracer development. Nuklearmedizin 2016; 55:51-62. [PMID: 27067793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2016] [Accepted: 01/25/2016] [Indexed: 06/05/2023]
Abstract
Optical imaging has long been considered a method for histological or microscopic investigations. Over the last 15 years, however, this method was applied for preclinical molecular imaging and, just recently, was also able to show its principal potential for clinical applications (e .g. fluorescence-guided surgery). Reviewing the development and preclinical evaluation of new fluorescent dyes and target-specific dye conjugates, these often show characteristic patterns of their routes of excretion and biodistribution, which could also be interesting for the development and optimization of radiopharmaceuticals. Especially ionic charges show a great influence on biodistribution and net-charge and charge-distribution on a conjugate often determines unspecific binding or background signals in liver, kidney or intestine, and other organs. Learning from fluorescent probe behaviour in vivo and translating this knowledge to radiopharmaceuticals might be useful to further optimize emerging and existing radiopharmaceuticals with respect to their biodistribution and thereby availability for binding to their targets.
Collapse
Affiliation(s)
- A Faust
- Andreas Faust, PhD, Waldeyerstr. 15, 48149 Münster, Germany, Tel. +49/(0)251/834 73 66, Fax +49/(0)251/834 93 13,
| | | | | | | |
Collapse
|
23
|
Bailey DL, Pichler BJ, Gückel B, Barthel H, Beer AJ, Bremerich J, Czernin J, Drzezga A, Franzius C, Goh V, Hartenbach M, Iida H, Kjaer A, la Fougère C, Ladefoged CN, Law I, Nikolaou K, Quick HH, Sabri O, Schäfer J, Schäfers M, Wehrl HF, Beyer T. Combined PET/MRI: Multi-modality Multi-parametric Imaging Is Here: Summary Report of the 4th International Workshop on PET/MR Imaging; February 23-27, 2015, Tübingen, Germany. Mol Imaging Biol 2015; 17:595-608. [PMID: 26286794 DOI: 10.1007/s11307-015-0886-9] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
This paper summarises key themes and discussions from the 4th international workshop dedicated to the advancement of the technical, scientific and clinical applications of combined positron emission tomography (PET)/magnetic resonance imaging (MRI) systems that was held in Tübingen, Germany, from February 23 to 27, 2015. Specifically, we summarise the three days of invited presentations from active researchers in this and associated fields augmented by round table discussions and dialogue boards with specific topics. These include the use of PET/MRI in cardiovascular disease, paediatrics, oncology, neurology and multi-parametric imaging, the latter of which was suggested as a key promoting factor for the wider adoption of integrated PET/MRI. Discussions throughout the workshop and a poll taken on the final day demonstrated that attendees felt more strongly that PET/MRI has further advanced in both technical versatility and acceptance by clinical and research-driven users from the status quo of last year. Still, with only minimal evidence of progress made in exploiting the true complementary nature of the PET and MRI-based information, PET/MRI is still yet to achieve its potential. In that regard, the conclusion of last year's meeting "the real work has just started" still holds true.
Collapse
Affiliation(s)
- D L Bailey
- Department of Nuclear Medicine, Royal North Shore Hospital, Sydney, Australia
- Faculty of Health Sciences, University of Sydney, Sydney, Australia
| | - B J Pichler
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany
| | - B Gückel
- Department of Interventional and Diagnostic Radiology, Eberhard Karls University, Tübingen, Germany
| | - H Barthel
- Department of Nuclear Medicine, Leipzig University, Leipzig, Germany
| | - A J Beer
- Department of Nuclear Medicine, Ulm University, Ulm, Germany
| | - J Bremerich
- Cardiothoracic Section, Department of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland
| | - J Czernin
- Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, USA
| | - A Drzezga
- Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany
| | - C Franzius
- Centre of Morphological and Molecular Diagnostics (ZeMoDi), MR- and PET/MRI; Centre of Nuclear Medicine and PET/CT, Bremen, Germany
| | - V Goh
- Division of Imaging Sciences and Biomedical Engineering, King's College London, London, UK
- Department of Radiology, Guy's and St Thomas' NHS Foundation Trust, London, UK
| | - M Hartenbach
- Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
| | - H Iida
- Department of Investigative Radiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan
| | - A Kjaer
- Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
| | - C la Fougère
- Department of Nuclear Medicine and Molecular Imaging, Eberhard Karls University Tübingen, Tübingen, Germany
| | - C N Ladefoged
- Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark
| | - I Law
- Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark
| | - K Nikolaou
- Department of Interventional and Diagnostic Radiology, Eberhard Karls University, Tübingen, Germany
| | - H H Quick
- Erwin L. Hahn Institute for MR Imaging, University of Duisburg-Essen, Essen, Germany
- High Field and Hybrid MR-Imaging, University Hospital Essen, Essen, Germany
| | - O Sabri
- Department of Nuclear Medicine, Leipzig University, Leipzig, Germany
| | - J Schäfer
- Department of Interventional and Diagnostic Radiology, Eberhard Karls University, Tübingen, Germany
| | - M Schäfers
- Department of Nuclear Medicine, University Hospital Münster, Münster, Germany
| | - H F Wehrl
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University, Tübingen, Germany
| | - T Beyer
- Center for Medical Physics and Biomedical Engineering, General Hospital Vienna, Medical University Vienna, 4L, Waehringer Guertel 18-20, 1090, Vienna, Austria.
| |
Collapse
|
24
|
Gran S, Schäfers M, Roth J, Vogl T. FRI0606 In Vivo Imaging of Phagocyte Migration in Inflammatory Processes by Fluorescent Cell Tracking. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.4636] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
25
|
Zenker S, Kondapuram M, Roth J, Hermann S, Faust A, Schäfers M, Vogl T. OP0155 New Optical in Vivo Imaging of the Alarmin S100A9 in an Experimental Autoimmune Model of Rheumatoid Arthritis. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
26
|
Schäfers M. Übersicht und Einführung. ROFO-FORTSCHR RONTG 2015. [DOI: 10.1055/s-0035-1550816] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
27
|
Faust A, Völler T, Busch F, Schäfers M, Roth J, Hermann S, Vogl T. Development and evaluation of a non-peptidic ligand for the molecular imaging of inflammatory processes using S100A9 (MRP14) as a novel target. Chem Commun (Camb) 2015; 51:15637-40. [DOI: 10.1039/c5cc07019h] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
We describe the development and first evaluation of a novel S100A9 specific molecular imaging probe (Cy5.5-CES271) for optical imaging of local inflammatory activity in vivo.
Collapse
Affiliation(s)
- A. Faust
- European Institute for Molecular Imaging (EIMI)
- University of Münster
- 48149 Münster
- Germany
- Cells-in-Motion Cluster of Excellence (EXC 1003–CiM)
| | - T. Völler
- Institute of Immunology
- University Hospital of Münster
- 48149 Münster
- Germany
| | - F. Busch
- European Institute for Molecular Imaging (EIMI)
- University of Münster
- 48149 Münster
- Germany
| | - M. Schäfers
- European Institute for Molecular Imaging (EIMI)
- University of Münster
- 48149 Münster
- Germany
- Cells-in-Motion Cluster of Excellence (EXC 1003–CiM)
| | - J. Roth
- Cells-in-Motion Cluster of Excellence (EXC 1003–CiM)
- University of Münster
- 48149 Münster
- Germany
- Institute of Immunology
| | - S. Hermann
- European Institute for Molecular Imaging (EIMI)
- University of Münster
- 48149 Münster
- Germany
- Cells-in-Motion Cluster of Excellence (EXC 1003–CiM)
| | - T. Vogl
- Cells-in-Motion Cluster of Excellence (EXC 1003–CiM)
- University of Münster
- 48149 Münster
- Germany
- Institute of Immunology
| |
Collapse
|
28
|
Lindner O, Burchert W, Schäfers M, Schaefer W. [Myocardial perfusion scintigraphy 2012 in Germany. Results of the 6th Query]. Nuklearmedizin 2013; 53:13-8. [PMID: 24193544 DOI: 10.3413/nukmed-0612-13-07] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2013] [Accepted: 09/04/2013] [Indexed: 11/20/2022]
Abstract
AIM The working group Cardiovascular Nuclear Medicine of the German Society of Nuclear Medicine presents the results of the 6th survey on myocardial perfusion scintigraphy (MPS) of the reporting year 2012. METHOD 278 questionnaires (177 private practices (PP), 78 hospitals (HO), 23 university hospitals (UH)) were evaluated. RESULTS MPS of 105,941 patients were reported. 95% [2005 = 80%] of MPS studies were conducted with (99m)Tc perfusion radiopharmaceuticals and only 5% with 201Tl. 79% [2009 = 76%] of the MPS were performed in PP, 15% [2009 = 17%] in HO, and 6% [2009 = 7%] in UH. Data from 108 centres which participated in all surveys from 2005 to 2012 showed an increase in MPS numbers of 4.0% (PP +6.1%, HO +18.2%, UH -18.3%). 29% of all participants (27% of PP, 31% of HO, and 26% of UH) noticed no change and 26% of all participants (28% of PP, 17% of HO and 35% of UH) an increase in their MPS requests since the 2009 query. The type of stress was pharmacological in 39% [2009 = 31%]. Of these 61% with adenosine (39% with exercise), 22% with regadenoson (51% with exercise), 14% with dipyridamole (60% with exercise), and 3% with dobutamine. Gated SPECT was performed in 73% [2009 = 56%] of all rest, in 70% [2009 = 56%] of all stress and in 67% [47%] of all stress and rest MPS. Only 36% [2009 = 33%] of the centres performed a quantification of all their studies with scores, whereas 41% [2009 = 52%] did not apply any quantification. 60% [2009 = 49%] of the MPS were requested by ambulatory care cardiologists. CONCLUSION The survey on MPS in Germany reveals a good conformity of imaging procedures with the current guideline. A positive development in MPS practice and referral can be stated. However, there is still some potential of MPS processing considering the quantitative perfusion analysis.
Collapse
Affiliation(s)
- O Lindner
- Priv.-Doz. Dr. Oliver Lindner, Institut für Radiologie, Nuklearmedizin und Molekulare Bildgebung, Herz- und Diabeteszentrum NRW, Georgstr. 11, 32545 Bad Oeynhausen, Tel. 057 31/97 13 09; Fax 057 31/97 21 90, E-Mail:
| | | | | | | |
Collapse
|
29
|
Korb-Pap A, Hillmann A, Heitzmann M, Bürgis S, Kollias G, Hermann S, Schäfers M, Gessner A, Pap T, Weide T, Pavenstädt H. THU0026 P62/SQSTM1 links reactive oxygen species formation and obesity to increased tnfalpha-mediated joint destruction via its signalling domains. Ann Rheum Dis 2013. [DOI: 10.1136/annrheumdis-2012-eular.1991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
30
|
Persigehl T, Stypmann J, Hermann S, Remmele S, Ring J, Schäfers M, Heindel W, Mesters R, Berdel W, Bremer C, Schwöppe C. Multi-modales Monitoring der anti-vaskulären tTF-NGR-Tumortherapie mittels USPIO- MRT, KM-Ultraschall (CEUS), Single-Photonen-Emissions-CT (SPECT) und Fluoreszenz-Bildgebung (FRI) im Xenograftmodell. ROFO-FORTSCHR RONTG 2013. [DOI: 10.1055/s-0033-1346201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
31
|
Moustakis C, Eschrich Y, Ernst I, Czekalla B, Büther F, Schäfers K, Schäfers M, Haverkamp U, Eich H. EP-1122: Use of a dynamic thorax phantom for radiation dose determination of a floating target in Extracranial Stereotactic RT. Radiother Oncol 2013. [DOI: 10.1016/s0167-8140(15)33428-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
32
|
Lindner O, Burchert W, Hacker M, Schaefer W, Schmidt M, Schober O, Schwaiger M, vom Dahl J, Zimmermann R, Schäfers M. [Myocardial perfusion scintigraphy - short form of the German guideline]. Nuklearmedizin 2013; 52:51-63; quiz N22. [PMID: 23370730 DOI: 10.3413/nukmed-0550-12-12] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2012] [Accepted: 01/08/2013] [Indexed: 11/20/2022]
Abstract
This guideline is a short summary of the guideline for myocardial perfusion scintigraphy published by the Association of the Scientific Medical Societies in Ger-many (AWMF). The purpose of this guideline is to provide practical assistance for indication and examination procedures as well as image analysis and to present the state-of-the-art of myocardial-perfusion-scintigraphy. After a short introduction on the fundamentals of imaging, precise and detailed information is given on the indications, patient preparation, stress testing, radiopharmaceuticals, examination protocols and techniques, radiation exposure, data reconstruction as well as information on visual and quantitative image analysis and interpretation. In addition possible pitfalls, artefacts and key elements of reporting are described.
Collapse
Affiliation(s)
- O Lindner
- Universitätsklinikum der Ruhr-Universität Bochum, Institut für Radiologie, Nuklearmedizin und Molekulare Bildgebung, Georgstr. 11, 32545 Bad Oeynhausen.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Hagenacker T, Schäfer N, Büsselberg D, Schäfers M. Analgesic ineffectiveness of lacosamide after spinal nerve ligation and its sodium channel activity in injured neurons. Eur J Pain 2012; 17:881-92. [DOI: 10.1002/j.1532-2149.2012.00260.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/12/2012] [Indexed: 11/10/2022]
Affiliation(s)
- T. Hagenacker
- Department of Neurology; University Hospital Essen; Germany
| | - N. Schäfer
- Department of Neurology; University Hospital Essen; Germany
| | - D. Büsselberg
- Weill Cornell Medical College in Qatar; Qatar Foundation-Education City; Doha; Qatar
| | - M. Schäfers
- Department of Neurology; University Hospital Essen; Germany
| |
Collapse
|
34
|
Waerzeggers Y, Monfared P, Viel T, Faust A, Kopka K, Schäfers M, Tavitian B, Winkeler A, Jacobs A. Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments. Br J Radiol 2012; 84 Spec No 2:S168-78. [PMID: 22433827 DOI: 10.1259/bjr/66405626] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023] Open
Abstract
A deeper understanding of the role of specific genes, proteins, pathways and networks in health and disease, coupled with the development of technologies to assay these molecules and pathways in patients, promises to revolutionise the practice of clinical medicine. Especially the discovery and development of novel drugs targeted to disease-specific alterations could benefit significantly from non-invasive imaging techniques assessing the dynamics of specific disease-related parameters. Here we review the application of imaging biomarkers in the management of patients with brain tumours, especially malignant glioma. In our other review we focused on imaging biomarkers of general biochemical and physiological processes related with tumour growth such as energy, protein, DNA and membrane metabolism, vascular function, hypoxia and cell death. In this part of the review, we will discuss the use of imaging biomarkers of specific disease-related molecular genetic alterations such as apoptosis, angiogenesis, cell membrane receptors and signalling pathways and their application in targeted therapies.
Collapse
Affiliation(s)
- Y Waerzeggers
- European Institute for Molecular Imaging, Westfaelische Wilhelms-University, Muenster, Germany
| | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Höltke C, Büther K, Compeer MG, de Mey JG, Schober O, Schäfers M, Heindel W, Riemann B, Bremer C. Optische Bildgebung der Endothelin-A-Rezeptor-Expression in murinen Schilddrüsen-Karzinom-Xenograften. ROFO-FORTSCHR RONTG 2012. [DOI: 10.1055/s-0032-1311459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
36
|
Bertrand J, Nitschke Y, Fuerst M, Hermann S, Schäfers M, Sherwood J, Nalesso G, Ruether W, Rutsch F, Dell'Accio F, Pap T. Decreased levels of nucleotide pyrophosphatase phosphodiesterase 1 are associated with cartilage calcification in osteoarthritis and trigger osteoarthritic changes in mice. Ann Rheum Dis 2012; 71:1249-53. [DOI: 10.1136/annrheumdis-2011-200892] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
37
|
Abstract
The assessment of endometrial safety is one of the key requirements for the clinical development of new products for hormone therapy (HT) to treat menopausal symptoms in women who have a uterus. Both the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) provide detailed guidance on the requirements for the evaluation of biopsies to prove endometrial safety. However, there are some discrepancies between the European and the US requirements, making it difficult to fulfil both guidelines simultaneously. In order to facilitate multinational clinical trials performed within clinical programs to develop novel HT products, we developed an approach considering both guidance documents as far as possible and proposed solutions for issues that are inconsistently described in these guidelines. A table with the required sample sizes is given. Our recommendation for a unified approach for the estimation of the hyperplasia rate for hormone therapies fulfils the intent of the recommendations of both the FDA and the EMA and thus leads to a globally harmonized drug development for hormone therapies.
Collapse
Affiliation(s)
- C Gerlinger
- Bayer Pharma AG - Global Clinical Statistics, Berlin, Germany
| | | | | | | | | |
Collapse
|
38
|
Lindner O, Burchert W, Schäfers M. Hohe Strahlenbelastung durch die Myokardszintigraphie: Ist die Dosis ein Problem? Dtsch Med Wochenschr 2011; 136:600. [DOI: 10.1055/s-0031-1274548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
39
|
Schäfers M. Molekulare Bildgebung von Herz und Gefäßen mit PET - Aktuelle Entwicklungen. ROFO-FORTSCHR RONTG 2011. [DOI: 10.1055/s-0031-1279011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
40
|
Hermann S, Stummer W, Kopka K, Wagner S, Faust A, Breyholz H, Hesselmann V, Schober O, Schäfers M, Jacobs A. Molekulare Bildgebung aktivierter Matrix-Metalloproteinasen (MMP) bei Patienten mit Gliomen. KLIN NEUROPHYSIOL 2011. [DOI: 10.1055/s-0031-1272775] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
41
|
Schäfers S, Hermann S, Kuhlmann M, Viel T, Kopka K, Schober O, Schäfers M, Jacobs A. Characterization of Experimental Gliomas by Multi-Modal Molecular Imaging. KLIN NEUROPHYSIOL 2011. [DOI: 10.1055/s-0031-1272659] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
42
|
Wenning C, Kloth C, Hermann S, Kuhlmann M, Schober O, Jacobs A, Schäfers M. Molekulare Bildgebung „shear-stress“ induzierter Atherosklerose der Arteria carotis communis mit small animal F-18-FDG-PET/CT. KLIN NEUROPHYSIOL 2011. [DOI: 10.1055/s-0031-1272774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
43
|
Hölzner E, Lippross V, Hermann S, Nagelmann N, Heselhaus J, Bohlen S, Kugel H, Deppe M, Sommer J, Bremer C, Nguyen H, Riess O, Hörsten SV, Schäfers M, Jacobs A, Reilmann R. PET/MRI-based phenotyping of a transgenic rat model for Huntington's disease - a 16 months follow-up study. KLIN NEUROPHYSIOL 2011. [DOI: 10.1055/s-0031-1272762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
44
|
Schmidt L, Spieker T, Hermann S, Humberg J, Koschmieder S, Marra A, Hillejan L, Schäfers M, Jakobs A, Berdel W, Müller-Tidow C, Wiewrodt R. Die lange nicht-kodierende MALAT-1 RNA begünstigt Tumorwachstum, Invasion und Migration von Lungenkarzinomzellen. Pneumologie 2011. [DOI: 10.1055/s-0031-1272240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Rahbar K, Seifarth H, Schäfers M, Stegger L, Spieker T, Hoffmeier A, Scheld HH, Schober O, Weckersser M. FDG-PET/CT in benign and malignant cardiac tumors. Thorac Cardiovasc Surg 2011. [DOI: 10.1055/s-0030-1268948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
46
|
Herzberg S, Fritz F, Rahbar K, Stegger L, Schäfers M, Dugas M. HIS-Based Support of Follow-Up Documentation - Concept and Implementation for Clinical Studies. Appl Clin Inform 2011; 2:1-17. [PMID: 23616857 DOI: 10.4338/aci-2010-08-ra-0047] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2010] [Accepted: 12/20/2010] [Indexed: 11/23/2022] Open
Abstract
OBJECTIVE Follow-up data must be collected according to the protocol of each clinical study, i.e. at certain time points. Missing follow-up information is a critical problem and may impede or bias the analysis of study data and result in delays. Moreover, additional patient recruitment may be necessary due to incomplete follow-up data. Current electronic data capture (EDC) systems in clinical studies are usually separated from hospital information systems (HIS) and therefore can provide limited functionality to support clinical workflow. In two case studies, we assessed the feasibility of HIS-based support of follow-up documentation. METHODS We have developed a data model and a HIS-based workflow to provide follow-up forms according to clinical study protocols. If a follow-up form was due, a database procedure created a follow-up event which was translated by a communication server into an HL7 message and transferred to the import interface of the clinical information system (CIS). This procedure generated the required follow-up form and enqueued a link to it in a work list of the relating study nurses and study physicians, respectively. RESULTS A HIS-based follow-up system automatically generated follow-up forms as defined by a clinical study protocol. These forms were scheduled into work lists of study nurses and study physicians. This system was integrated into the clinical workflow of two clinical studies. In a study from nuclear medicine, each scenario from the test concept according to the protocol of the single photon emission computer tomography/computer tomography (SPECT/CT) study was simulated and each scenario passed the test. For a study in psychiatry, 128 follow-up forms were automatically generated within 27 weeks, on average five forms per week (maximum 12, minimum 1 form per week). CONCLUSION HIS-based support of follow-up documentation in clinical studies is technically feasible and can support compliance with study protocols.
Collapse
|
47
|
Sommer C, Schäfers M. Was gibt es Neues beim neuropathischen Schmerz? Akt Neurol 2010. [DOI: 10.1055/s-0030-1265966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
48
|
Höltke C, Faust A, Breyholz HJ, Kopka K, Schober O, Riemann B, Bremer C, Schäfers M, Wagner S. Non-invasive approaches to visualize the endothelin axis in vivo using state-of-the-art molecular imaging modalities. Mini Rev Med Chem 2010; 9:1580-95. [PMID: 20088779 DOI: 10.2174/138955709791012210] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2009] [Accepted: 12/18/2009] [Indexed: 11/22/2022]
Abstract
The endothelin axis plays a major role in cardiovascular diseases and a number of human cancers. This review summarizes the work that has been published in the past ten years using labeled endothelin receptor ligands for the visualization of endothelin receptor expression in vivo.
Collapse
Affiliation(s)
- C Höltke
- Department of Nuclear Medicine, University Hospital Münster, Münster, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Herzberg S, Rahbar K, Stegger L, Schäfers M, Dugas M. Concept and Implementation of a Single Source Information System in Nuclear Medicine for Myocardial Scintigraphy (SPECT-CT data). Appl Clin Inform 2010; 1:50-67. [PMID: 23616827 DOI: 10.4338/aci-2009-12-ra-0017] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2009] [Accepted: 03/14/2010] [Indexed: 11/23/2022] Open
Abstract
OBJECTIVE Data for clinical documentation and medical research are usually managed in separate systems. We developed, implemented and assessed a documentation system for myocardial scintigraphy (SPECT/CT-data) in order to integrate clinical and research documentation. This paper presents concept, implementation and evaluation of this single source system including methods to improve data quality by plausibility checks. METHODS We analyzed the documentation process for myocardial scintigraphy, especially for collecting medical history, symptoms and medication as well as stress and rest injection protocols. Corresponding electronic forms were implemented in our hospital information system (HIS) including plausibility checks to support correctness and completeness of data entry. Research data can be extracted from routine data by dedicated HIS reports. RESULTS A single source system based on HIS-electronic documentation merges clinical and scientific documentation and thus avoids multiple documentation. Within nine months 495 patients were documented with our system by 8 physicians and 6 radiographers (466 medical history protocols, 466 stress and 414 rest injection protocols). Documentation consists of 295 attributes, three quarters are conditional items. Data quality improved substantially compared to previous paper-based documentation. CONCLUSION A single source system to collect routine and research data for myocardial scintigraphy is feasible in a real-world setting and can generate high-quality data through online plausibility checks.
Collapse
|
50
|
Hagenacker T, Czeschik JC, Schäfers M, Büsselberg D. Sensitization of voltage activated calcium channel currents for capsaicin in nociceptive neurons by tumor-necrosis-factor-alpha. Brain Res Bull 2010; 81:157-63. [PMID: 19818386 DOI: 10.1016/j.brainresbull.2009.09.012] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2009] [Revised: 09/16/2009] [Accepted: 09/27/2009] [Indexed: 10/20/2022]
Abstract
It is known that application of tumor-necrosis-factor-alpha (TNF-alpha) sensitizes neuronal calcium channels for heat stimuli in rat models of neuropathic pain. This study examines whether TNF-alpha modulates the capsaicin-induced effects after transient receptor potential vanilloid (TRPV)-1 receptor activation on voltage activated calcium channel currents (I(Ca(V))). TRPV-1 receptors are activated by heat and play an important role in the pathogenesis of thermal hyperalgesia in neuropathic pain syndromes, while voltage activated channels are essential for transmission of neuronal signals. Eliciting I(Ca(V)) in DRG neurons of rats by a depolarization from the resting potential to 0 mV, TNF-alpha (100 ng/ml) reduces I(Ca(V)) by 16.9+/-2.2%, while capsaicin (0.1 microM) decreases currents by 27+/-4.3%. Pre-application of TNF-alpha (100 ng/ml) for 24h results in a sensitization of I(Ca(V)) to capsaicin (0.1 microM) with a reduction of 42.8+/-4.4% mediated by TRPV-1. While L-type (36.6+/-5.2%) and P/Q-type currents (35.6+/-4.1%) are also sensitized by TRPV-1 activation, N-type channel currents are most sensitive (74.5+/-7.3%). The capsaicin-induced shift towards the hyperpolarizing voltage range does not occur when TNF-alpha is applied. Summarizing, TNF-alpha sensitizes nociceptive neurons for capsaicin.
Collapse
Affiliation(s)
- T Hagenacker
- Universitätsklinikum Essen, Klinik für Neurologie, Hufelandstr. 55, 45122 Essen, Germany.
| | | | | | | |
Collapse
|